EP1849465A4 — AGENT FOR CONTROLLING THE FUNCTION OF THE GPR34 RECEPTOR
Assigned to Takeda Pharmaceutical Co Ltd · Expires 2008-12-24 · 17y expired
What this patent protects
An agent for controlling the function of a GPR34 receptor, the agent containing a compound represented by the formula [wherein ring A represents an optionally substituted homocycle or heterocycle; P represents a bond or spacer; ring D represents an optionally substituted, monocyc…
USPTO Abstract
An agent for controlling the function of a GPR34 receptor, the agent containing a compound represented by the formula [wherein ring A represents an optionally substituted homocycle or heterocycle; P represents a bond or spacer; ring D represents an optionally substituted, monocyclic aromatic ring optionally fused to a 5- to 7-membered ring; V represents a bond or a group represented by -CR14=CR15- or -N=CR16- (wherein R14, R15, and R16 each represents hydrogen or an optionally substituted hydrocarbon group); Q represents a bond or spacer; and W represents carboxy or a group biologically equivalent to carboxy], a salt of the compound, or a prodrug of either.
Drugs covered by this patent
- Xtandi (enzalutamide) · Astellas Pharma
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.